News | August 18, 2010

AHA Says Cardiac Computed Tomography is Safe, Accurate, Cost-Effective


August 18, 2010 - Cardiac computed tomography (CT) was found to be safe, accurate, and cost-effective in low risk patients in a recent scientific statement published by the American Heart Association (AHA), titled “Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain.”

The paper summarizes the use of cardiac CT angiography as “Computed tomography coronary angiography has also shown promise in this setting. A negative accelerated diagnostic protocol evaluation allows discharge, whereas patients with positive findings are admitted. This approach has been found to be safe, accurate, and cost-effective in low-risk patients presenting with chest pain.”

The use of CT angiography is rapidly expanding, primarily due to well-published studies demonstrating cost effectiveness and safety in this population. Hospitals and cardiologists are increasingly turning to this test to determine who of those presenting to the emergency room can be safely discharged from the hospital in a timely fashion.

New, large randomized studies that were already presented, but not yet published, further reinforce the utility of this modality and the safety, efficacy and cost savings compared to other imaging tests.

These guidelines, in association with NICE guidelines recently published on the same topic, reiterate the important and growing role of cardiac CT angiography and calcium scoring as rapid methods to triage patients in the emergency department safely and most cost-effectively than other imaging modalities," said Matthew J. Budoff, M.D., FSCCT, professor of medicine at the David Geffen School of Medicine at UCLA, director of cardiac CT at Los Angeles Biomedical Research Center at Harbor UCLA Medical Center in Torrance, CA and president of the Society of Cardiovascular Computed Tomography (SCCT).

For more information: www.SCCT.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now